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ABSTRACT 
Background: Pediatric inpatients in United States healthcare settings may be particularly 
vulnerable with respect to methicillin-resistant Staphylococcus aureus (MRSA) infection 
and transmission.  Although infection prevention and control protocols have well been 
established for MRSA and for adult inpatients, there are few current guidelines available 
on how to address MRSA prevention and control in pediatric inpatients.   
Objectives: To systematically identify, describe, and evaluate the quality of the current 
literature on infection prevention and control strategies for preventing the transmission of 
methicillin-resistant Staphylococcus aureus (MRSA) in United States pediatric inpatient 
settings.   
Search methods: In June-August 2015, Campbell Collaboration Library, Cochrane 
Library, PubMed, MEDLINE, Biological Abstracts, CINAHL Plus, and Web of Science 
was searched for studies published between January of 2005 and December 2015 by 
using relevant key terms for pediatric patients (ex, children, infant, newborn, neonate) 
and prevention and control of MRSA.   
Selection criteria: All primary data studies on infection prevention and control 
interventions for healthcare associated MRSA in United States pediatric inpatient settings 
were eligible for inclusion.  
Data collection and analysis: Two authors independently reviewed the results of the 
searches. Another author was consulted for any discrepancies between categorization of 
articles. Data extraction was conducted by one author and was checked by a second 
author. 
Main results: 1,619 studies were initially identified, of which 21 studies met the criteria 
for inclusion.  Of the studies that met inclusion criteria, one was a randomized control 
trial, thirteen were retrospective cohort studies, four were before and after studies, two 
were prospective cohort studies and one was a retrospective case finding.  Three studies 
(Song (2010), Robicsek (2009), and Gregory (2009)) found that Mupirocin or antibiotic 
treatment did not eradicate MRSA colonization consistently and were unsuccessful in 
eliminating continuing transmission of MRSA.  However, the study by Delaney found 
that there was a significant reduction in rates of S. aureus infection when comparing 
Mupirocin prophylactic period with the control period.  Another two studies (Constantini 
and Kjonegaard) found that screening was not identifying all of the MRSA cases, and 
that HA-MRSA infection rates did not decline after implementation of ICU screening, 
thus proving that this method was ineffective in regards to decreasing transmission and 
incidence of MRSA infections. 
Conclusion: There is a lack of research evaluating the effects on MRSA transmission of 
infection prevention and control strategies in pediatric inpatient settings. More resources 
should be devoted to understand the epidemiology of MRSA amongst the pediatric 
inpatient population as well as continued research interventions to establish prevention 
and control protocols for this vulnerable population.    
KEYWORDS Prevention, Control, MRSA, Neonates, Infant, Pediatrics, Children, 
Newborns, NICU, PICU 
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CHAPTER I. INTRODUCTION 
According to the Department of Health and Human Services, about 1 in every 25 
inpatients has an infection associated with hospital care, costing billions of dollars and 
about ten thousand lives annually (DHHS, 2015).  It is therefore imperative that we treat 
hospital-acquired infections in order to reduce excessive expenditures and improve 
patient outcomes.  One of the most common hospital acquired infections is methicillin-
resistant Staphylococcus aureus (MRSA).  MRSA is an opportunistic gram-positive 
bacteria that has in recent years become a serious healthcare as well as community threat.  
 Staphylococcus aureus asymptomatically colonizes the skin and anterior nares 
(nostrils) of approximately one-third of the human population at any given time and two 
out of 100 people are carriers for MRSA (CDC, 2013). Consequently, outbreaks of S. 
aureus and MRSA are extremely common as many in the population do not know that 
they are carriers of the bacteria (Williams, et al., 2010; CDC, 2013).  Unfortunately in 
today’s society, Staphylococcus aureus has become resistant to common medications 
prescribed to treat staph infections.  In order to fully understand how MRSA became 
resistant to several broad-spectrum antibiotics, it is important to understand the history 
that transformed this bacteria.   
Although Staphylococcus aureus itself has been around for billions of years, it 
was the overuse of Alexzander Flemmings’ development of penicillin in 1928 that caused 
the bacteria to become resistant to antibiotics due to acquisitions of genes producing b-
lactamase (Moellering, 2012).  In 1959, Methicillin was introduced as a new antibiotic 
and within a two-year span, methicillin-resistant Staphylococcus aureus developed. It is 
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also important to note that according to Mayhall (2012), although MRSA got its name 
from being methicillin-resistant, MRSA is now not only resistant to anti-staphylococcal 
penicillins such as nalcillin and oxacillin but is also resistant to beta-lactam antibiotics 
from first through fourth generations of cephalosporins and carbapenems. Since 1961, 
MRSA has spread throughout the world, causing many healthcare, community, and 
livestock associated infections.  According to the CDC (2013), community acquired 
MRSA infections are most associated with skin infections, but healthcare associated 
infections are associated with life-threatening bloodstream infections (or MRSA 
bacteremia), pneumonia, and surgical site infections.  For the purpose of this systematic 
review, we will be focusing solely on hospital and healthcare associated infections, 
however it is important to note the growing prevalence of community and livestock 
associated infections.    
Nosocomial infections (hospital acquired/healthcare associated) are those that 
were not present in the patient prior to hospitalization and occur usually 48-72 hours after 
admittance or within 10 days of discharge from the hospital (Jacobs, 2014).  Healthcare 
associated infections (HAIs) are important to understand because they can cause life-
threatening illnesses that often can be prevented if proper protocol is followed.   
MRSA is a nosocomial infection that is associated with high morbidity and 
mortality rates. According to Boucher et al; (2008), in 2005 MRSA infections killed an 
estimated 19,000 hospitalized Americans, which is higher than combined AIDS, 
Tuberculosis, Viral hepatitis, SARS, and Avian influenza deaths in the United States.  
When looking at medical device related deaths, another study by Hanberger et al; (2011) 
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analyzed 1265 ICUs from 75 countries and found that in ICU patients, MRSA infections 
were independently associated with nearly 50% more hospital deaths when compared to 
MSSA infections of ICU patients.  MRSA has been a common cause of Central Line-
associated Bloodstream Infection (CLABSI), hospital-acquired pneumonia, Catheter-
associated Urinary Tract Infections (CAUITs), wound infections, and Surgical Site 
Infections (SSIs) (Mayhall, 2012).  According to Mayhall (2012), blood stream infections 
caused by MRSA have mortality rates that range from 20% to more than 35%.  MRSA 
has also been associated with longer lengths of stay, as well as increased health costs 
(Mayhall, 2012).  Corriere & Deckner (2008) and Noskin and colleagues (2005) have 
shown that the length of stay for inpatients with S. aureus infection is three times longer 
than that of other patients.  They also discuss that when looking at MRSA vs. Methicillin-
sensitive Staphylococcus aureus (MSSA), the average length of stay for MRSA 
infections was 20.1 days longer when compared to MSSA infections, resulting in a 55% 
longer length of stay.   
MRSA affects mostly those with compromised immune systems, those who have 
previously taken antibiotics, the elderly, and those with underlying diseases (CDC, 2013).  
Because MRSA affects mostly those with compromised immune systems, there is a 
higher risk associated with inpatients in the ICU, among those who recently had surgery 
or in those who have invasive medical devices such as catheters or intravenous lines.   
According to the CDC (2013), the primary mode of transmission for hospital-
acquired MRSA is through person-to-person contact, primarily through healthcare worker 
contact with patients or, less frequently, through patient to patient contact.  Contaminated 
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surfaces and medical equipment are the second most common mode of transmission of 
MRSA.  Due to the fact that MRSA is an opportunistic bacteria that most often impacts 
individuals with impaired immune systems, it is extremely important that prevention and 
control methods are standardized throughout inpatient settings in order to reduce the risk 
of spreading.  
In addition to the risk factors discussed above, Mayhall (2012) discusses certain 
healthcare delivery risk factors that have been associated with an increased risk of MRSA 
infection in inpatient care.  Mayhall (2012) found that risk of MRSA increases as the 
prevalence of MRSA among hospital patients increases, that risk increases among 
persons admitted to a hospital room in which prior room occupant was colonized or 
infected with MRSA, and that healthcare worker hand hygiene practices influence risk 
for the patient.  Lastly, increased MRSA risks have been associated with staffing deficits 
and patient overcrowding, thus providing evidence that contact precautions and 
environmental cleaning are paramount to preventing hospital acquired infections 
(Mayhall, 2012).  
Mayhall (2012) also discussed that MRSA was the cause of 56.8% of S. aureus 
healthcare-associated pneumonia, 48.6% of S. aureus hospital-acquired pneumonia, and 
34.4% of S. aureus Ventilator-associated Pneumonia (VAP), although associating 
mortality to those who acquired S. aureus VAP is debatable amongst researchers. The 
National Healthcare Safety Network (NHSN) reported 2,045 S. aureus SSI cases from 
2006-2007, resulting in 49% of those S. aureus SSI cases were due to MRSA (Calfee, 
2014).  Not only is MRSA highly associated with the cause of theses infections, but delay 
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in recognizing and treating MRSA can have severe consequences such as higher 
mortality rates (Corrier & Deckner, 2008).   
Because healthcare-associated MRSA is associated with high morbidity and 
mortality, MRSA is also associated with high costs of care.  Jacobs (2014) found that in 
the United States, HAIs infect 1.7 million patients annually, account for 99,000 deaths, 
and cost approximately $35.7 to $45 billion.  In order to assess how much cost was 
attributed per patient, a cohort study was conducted at the U.S. Department of Veterans 
Affairs system between 2007-2010 that analyzed inpatient as well as pharmacy costs 
during a year following the discharged MRSA patient (Nelson et al., (2015).    Nelson et 
al., (2015) found that 3,599 of the 369,743 inpatients had positive MRSA cultures.  After 
matching positive MRSA cultured patients to controls, patients were followed for a year 
and the study found that those MRSA patients had an increased post-discharge pharmacy 
cost average of $776 and an increased inpatient cost average of $12,167 (Nelson et al., 
2015).  The study also found that MRSA patients were at an increased risk for 
readmission, had more prescriptions, and more inpatient days.   This study provides 
evidence that the cost associated with MRSA patients is substantially higher than that of 
inpatients without MRSA.  Thus, it is important to implement stricter prevention and 
control policies as to not only improve patient health but as to reduce extraneous 
spending on a national level.   
According to the Active Bacterial Core Surveillance Report in 2012, the total 
estimated cases of MRSA infection in the United States was 75,309 with an incidence 
rate of 23.99 (CDC, 2012).  The national metric for Healthy People 2020 and Department 
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of Health and Human Services Action Plan to Prevent Healthcare-Associated Infection 
shows that there have been 23,000 fewer cases in the United States in 2012 when 
compared to the baseline of 2007-2008, depicting a -30.80% change in healthcare 
associated infections (CDC, 2012).  Another study by the National Healthcare Safety 
Network (NHSN) found that rates of MRSA bloodstream infections occurring in 
hospitalized patients fell almost 50% from 1997-2007 (CDC, 2013).  A study published 
by the Journal of American Medical Association Internal Medicine showed that invasive 
MRSA hospital acquired infections declined by 54% from 2005 to 2011 as well as 9,000 
fewer deaths in 2011 (CDC, 2013).  The decreasing rate of infections provides evidence 
that there are fewer morbidities and mortalities from MRSA infections.   
However, the University of Chicago Medicine (UCM) and the University 
Healthcare Consortium (UHC) published data in 2012 that estimated that the rates of 
MRSA in U.S. academic medical centers from 2003-2008 had actually doubled (David, 
et al., 2012).  Jacobs (2014) discusses that this difference between the UCM and UHC 
study and the CDC data could possibly be due to the fact that the CDC only looks at 
invasive infections, which excludes skin infections that were included in the UCM and 
UHC study.  Another study conducted by Jarvis et al., (2012) surveyed all U.S. 
Association for Professionals in Infection Control and Epidemiology, members in order 
to assess the prevalence of MRSA from August 1 to December 30, 2010 for all inpatients.  
The study found that the overall MRSA prevalence rate was 66.4 per 1,000 inpatients, 
which was higher than rate reported in their 2006 study, which used the same 
methodology.  Thus, it appears that there is a decrease in MRSA invasive infections but 
an increase in the overall prevalence of MRSA in inpatients.   
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Although there is an improvement due to the decrease in the severity of and risk 
of mortality as a result of infections, healthcare associated MRSA infections were not 
significantly reduced among pediatric populations from 2005-2010, indicating that there 
needs to be further research as to why there is an overall improvement among adults but 
not for pediatric inpatients (Iwamoto et al., 2013).  It is important to study pediatric 
populations because according to Milstone et al., (2011) 8.5% of pediatric patients that 
were colonized with MRSA on admission developed a MRSA infection.  Even more 
staggering is the fact that 47% of patients who became colonized with MRSA in the 
pediatric ICU developed MRSA infections (Milstone et al., 2011).  In comparison, 
Hudson et al., (2012) found that the rates of MRSA carriage to be 6-12% in general 
hospital patients and 9-24% in ICUs.  MRSA is a common bacterial infection amongst 
children, especially in the NICU due to their susceptibility to infections.  Various 
strategies for prevention and eradication have been used with various rates of success, but 
implementation of standardized prevention methods needs to be developed specifically 
for pediatrics.  
 Guidelines for prevention of healthcare associated MRSA (HA-MRSA) currently 
exist from the Center for Disease Control and Prevention, but there is limited evidence 
about best practices implementation for MRSA prevention for pediatrics.  The purpose of 
this study was to conduct a systematic review in order to evaluate the current state of the 
science with respect to MRSA interventions in order to reduce the transmission and 
incidence of MRSA infections in pediatric inpatient settings in the United States.  This 
systematic review included literature found from 2005-2015 and specifically focused on 
inpatient pediatrics.  This study aimed to  
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1. Identify interventions for the prevention of hospital-acquired MRSA in 
pediatrics in the United States 
2. Explore which prevention interventions appear to be most effective as defined 
by decrease in transmission or incidence of infection 
3. Develop informed suggestions to policy makers regarding current hospital-
acquired MRSA prevention protocols for pediatrics  
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CHAPTER II. LITERATURE REVIEW 
 Numerous strategies to reduce MRSA colonization and invasive infections have 
been published, but very few of these have focused on pediatric patients.  This is 
problematic due to the fact that we cannot generalize results from adult studies to the 
pediatric patients due to the fact that pediatric patients cannot take the same dosages, they 
have weaker immune systems, and are often more susceptible to infections.  The article 
released in 2014 by Nelson et al., titled “One size does not fit all: why universal 
decolonization strategies to prevent methicillin-resistant Staphylococcus aureus 
colonization and infection in adult intensive care units may be inappropriate for neonatal 
intensive care units” is important to note because it articulates why it is not necessarily 
appropriate to apply strategies used with adult populations to pediatric populations.  The 
article discusses the recently published REDUCE MRSA TRIAL, a large multicenter, 
randomized controlled trial that compared the efficacy of three surveillance and 
decolonization strategies for reducing MRSA colonization and infection in adult ICUs 
(Nelson et al., 2014).  Some of the results of the trial that were intended for adult ICU 
patients only has trickled down to the pediatric ICU patient population. Nelson (2014) 
discussed that many prevention control procedures (such a Chlorohexidine) that have 
been implemented in adult settings have not been studied in pediatric populations, or 
worse are shown to have serious health implications (Nelson et al., 2014).   
Because this systematic review is concerned with prevention and control 
interventions of MRSA in the pediatric inpatient population, it is important to review 
current policies of prevention or control of MRSA in this populations.  Another important 
aspect that warrants review is the prevalence and cost of MRSA infections in the 
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pediatric inpatient population in order to assess the magnitude of the issues and lastly 
review current prevention methods for this population.  Because the REDUCE MRSA 
TRIAL influenced protocols published by the AHRQ and CDC, it is important to next 
review these protocols and discuss the gaps in the literature.   
In this section, current guidelines and published protocols by the Center for 
Disease Control and Prevention and the Department of Health and Human Services will 
be discussed.  More specifically, the Agency for Healthcare Research and Quality 
(AHRQ) provides two guidelines that will be reviewed.  Although all of these guidelines 
make suggestions related to MRSA prevention/control among pediatric inpatients, none 
of these guidelines are specific to this population and prevention of MRSA, providing 
evidence that there is a gap in guidelines specifically intended for pediatric inpatients.   
The first guideline from AHRQ titled “Diagnosis and management of complicated 
intra-abdominal infection in adults and children: guidelines by the Surgical Infection 
Society and the Infectious Disease Society of America” by Solomkin et al., (2010) is 
important to discuss because MRSA is associated with surgical site infections (SSIs).  
The guideline provides regimens for healthcare associated infections including MRSA 
therapy.  The author searched through both primary and secondary sources as well as 
electronic databases in order to develop recommendations.  The guidelines are based on 
evidence from randomized clinical trials from 2002-2008, which used antimicrobials for 
the treatment of intra-abdominal infection.  A panel of experts in the infectious diseases, 
surgery, pharmacology, and microbiology prepared these guidelines for the IDSA 
(Infectious Disease Society of America).   
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The guidelines suggest that those who are known to be colonized with MRSA or 
are at risk of having an infection due to prior treatment failure and antibiotic exposure 
should receive empiric antimicrobial coverage (Solomkin et al., 2010).  Also, 
Vancomycin is recommended for treatment of suspected or positive identified MRSA 
infection for intra-abdominal infections.  However, routine use of broad-spectrum agents 
are not indicated for all pediatric inpatients with low suspicion or complication of 
infection.   
For pediatrics, the guidelines discuss that selection of specific antimicrobial 
therapy with infection should be based on community vs. healthcare-associated infection 
source, severity of illness, and the safety of antimicrobial agents in specific pediatric age 
groups.  For neonates, broad-spectrum antibiotics may be used with vancomycin being 
the primary antibiotic used for MRSA control.  However, the guideline also suggest that 
therapy for pediatric patients with intra-abdominal infection is constrained by safety 
concerns and that some forms of antibiotics such as tetracyclines and parenteral 
fluorquinolones are not recommended when other alternatives exist.  This shows that 
there is no clarity of when broad-spectrum antibiotics use is appropriate when treating 
neonates.  In conclusion, the guideline did not mention prevention or control of MRSA in 
pediatrics, and in fact it provides very limited information with respect to the treatment of 
MRSA amongst pediatric patients.   
The second guideline from AHRQ “Clinical practice guidelines by the Infectious 
Diseases Society of America for the treatment of methicillin-resistant Staphylococcus 
aureus infections in adults and children” (Liu et al., 2011) discusses key prevention and 
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control guidelines for preventing, controlling, and treating of MRSA.  This guideline 
provides details about the management of MRSA in skin and soft-tissue infections 
(SSTIs), the management of recurrent MRSA SSTIs, bacteremia, MRSA pneumonia, 
MRSA bone and joint infections, and MRSA central nervous system infections.  An 
expert panel reviewed and synthesized the evidence published between 1961 and 2010.  
Literature searches of PUBMED of the English-language literature were performed from 
using terms “methicillin-resistant Staphylococcus aureus” or “MRSA”.   
 The results of this review suggest that, for pediatrics, almost all MRSA infections 
are controlled and treated with Vancomycin; however, there is limited data about the 
dosage efficacy, and safety of antibiotic usage.  Consequently, the guideline suggests that 
additional studies should be conducted.  Current literature does suggest that in neonates 
and young infants, topical treatments as an implementation of control methodology is 
standard.  The guideline recommends that for more-extensive diseases or in premature or 
very-low birth weight, vancomycin or clindamycin should be used.  For SSTIs, antibiotic 
therapy is only recommended for the cohorts associated with extremes of age (ex. 
pediatrics and elderly), but topical treatment is best approach.   
The guidelines also have found that preventive educational messages on personal 
hygiene and appropriate wound care are recommended for all patients with SSTIs.  Also 
environmental hygiene measures should be considered, with a focus cleaning efforts on 
high-touch surfaces (i.e. surfaces that come into contact with people’s bare skin such as 
door knobs, toilet seats).  This recommendation is congruent with findings reported by 
Giannini et al., (2009) which found that in a children’s cancer hospital, alcohol wipes on 
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toilet seats prior to use resulted in a 50-fold reduction in mean daily bacterial counts and 
eliminated MRSA, thus providing additional evidence that environmental 
decontamination is key to avoiding spread of MRSA in pediatric patients.  Lastly, 
decolonization should be considered in selected cases based on severity of infection, 
recurrence of MRSA despite implementing wound care and hygiene measures. In 
conclusion, the guidelines published by Liu et al., (2011) did provide some information 
on control and preventive measures, but in general the guidelines were more focused on 
the adult inpatient population rather than on pediatric inpatient populations.   
Another guideline that is important to discuss is the recent “Strategies to Prevent 
Methicillin-Resistant Staphylococcus aureus Transmission and Infection in Acute Care 
Hospitals: 2014 Update” by Calfee et al., (2014).  The development of this guideline was 
sponsored by the Society for Healthcare Epidemiology of America (SHEA) and was a 
product of collaboration from the Infectious Disease Society of America, the American 
Hospital Association, the Association for Professionals in Infection Control and 
Epidemiology, and The Joint Commission.  It is one of the most comprehensive 
guidelines to date with respect to MRSA prevention and treatment in inpatient settings.  
The guideline’s main purpose is to highlight practical recommendations for implementing 
and prioritizing MRSA prevention efforts.  The authors suggest that basic practices for 
preventing MRSA transmission and infection are recommended for all acute care 
hospitals and that active surveillance testing should be implemented when basic practices 
are insufficient.   
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Calfee and colleagues suggest that basic prevention practices include conducting a 
MRSA risk assessment, educating healthcare personnel regarding MRSA, ensuring 
compliance with hand hygiene recommendations, ensuring proper cleaning and 
disinfection of equipment and environment, ensuring compliance with contact 
precautions for MRSA-colonized and infected patients, and implementing a MRSA 
monitoring program.  If these steps are insufficient, compliance with basic practices 
needs to be assessed.  If compliance with basic practices is met and MRSA is not 
effectively controlled, the guidelines suggest instituting one or more special approaches.  
The list of special approaches include conducting active surveillance testing for MRSA 
colonization among patients, implementing MRSA decolonization therapy, implementing 
universal gowns and gloves, continuing to monitor MRSA rates, and continuing a MRSA 
reporting and accountability system.   
These are the general guidelines for prevention and control of MRSA among 
acute inpatient facilities.  However, the guidelines indicate that, in pediatric populations, 
there needs to be more research on prevention protocols.  For example, the guideline 
reports that limited data are available on use of chlorohexidine for routine patient 
cleansing for prevention of MRSA outside of the adult ICU setting (Rupp et al., 2012).  
Also, when universal decolonization is suggested, the guidelines report that a few quasi-
experimental single-center studies in the neonatal ICUs have shown a benefit of universal 
decolonization with topical mupirocin in control of MRSA outbreaks and endemic 
MRSA disease (Hitomi et al., 2000 and Delaney et al., 2013).   
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The guidelines continue to report the fact that outside of neonates, universal 
decolonization has not been studied in hospitalized children.  Lastly, the guidelines report 
that the neonatal ICU has a number of unique characteristics that should be considered 
when an AST program is being implemented such as the size of the NICU, the number of 
beds per pod, if any neonates such as twins share beds, etc. (Calfee et al., 2014).  The 
census after reading the guidelines from Calfee et al., (2014) suggest that there needs to 
be more research conducted in the area of prevention and control of MRSA in pediatric 
inpatients.   
Echoing this information is the information published in the National Action Plan 
to Prevent Health Care-Associated Infections: Road Map to Elimination published in 
April of 2013.  The National Action Plan is a product of the Federal Steering Committee 
for the Prevention of Health Care-Associated Infections, which was established in 2008.  
The steering committee’s members include clinicians, scientists, and public health leaders 
form the Department of Defense, the Department of Health and Human Services, the U.S. 
Department of Labor, and the U.S. Department of Veterans Affairs.  The purpose of the 
Steering Committee is to accelerate progress toward national infection reduction goals.   
In the National Action Plan of 2013, the Steering Committee stated that in 2005, 
there was an estimated 94,000 invasive MRSA infections in the U.S. which were 
associated with nearly 18,000 deaths.  Of these invasive infections, 86% were associated 
with health care delivery (Kallen et al., 2010).  Fortunately, rates of invasive health care-
associated MRSA infections have decreased, but the optimal strategy for preventing and 
controlling health care-associated MRSA has not been fully reached.  In their discussion 
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about the current gaps in knowledge and practice, the Steering Committee suggest the 
need to understand the epidemiology of MRSA outside the adult ICU, especially in the 
pediatric population. The committee also discussed the need to facilitate an understanding 
of the role of various prevention strategies in reducing transmission of MRSA.  Also an 
important issue that is discussed is the need to translate accepted prevention practices to 
areas outside the adult ICU, thus providing evidence that more research needs to be 
conducted in order to adequately represent the pediatric population. 
After review all current MRSA prevention and control guidelines, there is a 
consensus that there needs to be more research conducted for prevention and control of 
MRSA in pediatric inpatient settings. Now that we have a knowledge basis of current 
guidelines, it is important to review the prevalence of MRSA in pediatric inpatient 
settings in order to understand the magnitude of the problem.   
The article by Kallen et al., (2010) surveyed 9 metropolitan areas covering a 
population of approximately 15 million persons.   Their main objective was to describe 
changes in rate of invasive health care-associated MRSA infections from 2005-2008.  
Kallen et al., (2010) found that there were 21,503 episodes of invasive MRSA infections, 
17,508 were healthcare associated and that the rate of hospital-onset invasive MRSA 
infections was 1.02 per 10,000 in 2005 and decreased 9.4% per year (95% confidence 
interval [CI], 14.7% to 3.8%; P = .005).  Although this shows vast improvement in our 
healthcare settings, it is important to focus on data available for pediatric populations in 
order to see if any improvements have been achieved there.   
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Song et al., (2013) published an article that discusses the incidence of MRSA 
infection in a children's hospital in the Washington metropolitan area from 2003 - 2010.  
They found that in 2004 there were 0.93 per 1,000 patient-encounter MRSA infections, 
then dramatically increased to 5.34 per 1,000 patient-encounter MRSA infections in 2007 
and decreased to 3.77 per 1,000 patient-encounters by the end of 2010 (Song et al., 
2013).  Another study conducted by Gerber et al., (2010) performed a retrospective, 
observational study using the Pediatric Health Information System from more than 40 US 
children’s hospitals.  The study used discharge codes during the period of January 2002 
to December 31st, 2007 and found that there was a significant increase in cases of MRSA 
infection (from 6.7 cases per 1,000 admissions in 2002 to 21.1 cases per 1,000 
admissions in 2007).  This research shows that there is a need for prevention protocol 
development at children’s hospitals across the nation.   Next, we will focus more 
specifically at the trends in incidence of MRSA in the NICU.   
According to the National Nosocomial Infection Surveillance System, incidence 
of late-onset MRSA infections in NICUs increased from 0.7 to 3.1 infection per 10,000 
patient days from 1995-2004, showing an increase of 308% late-onset infections (Lessa 
et al., 2009).  This information is important because prevention methods will have to be 
altered to specifically address late-onset MRSA infections.  A better picture of the 
colonization in neonatal and pediatric ICUs can be seen in the meta-analysis conducted in 
2014 by Zervous et al.  The meta-analysis identified 18 articles that were clinical studies 
on MRSA colonization published from 2006-2013.  The prevalence of colonization of 
MRSA among NICU patient on admission was 1.5% (95% CI 0.9%-2.2%) compared to 
the 3.0% (95% CI 1.9%-4.5%) among PICU patients.  According to Zervous et al., 
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(2014), “the acquisition rate was 4.1% (95% CI 1.2%–8.6%) among the neonatal and 
pediatric population, whereas among the neonatal population alone, 6.1% (95% CI 2.8%–
10.6%) of patients acquired MRSA during the NICU stay”.  This supports all other 
research discussed where steps need to be taken to prevent and control MRSA in the 
vulnerable pediatric population.  This population should be treated differently than the 
adult population and should have specific protocols dedicated to pediatric inpatient 
facilities.  More research needs to be conducted in order to assess current incidence rates 
and trends in MRSA pediatric inpatients as well as to deduce which prevention and 
control policy has quantitatively shown a reduction in MRSA infection rates in pediatric 
inpatients.   
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Prevention of hospital-acquired methicillin-resistant staphylococcus aureus in U.S. 
pediatric inpatients: a systematic review 
 R. See, V. Mahathre, A. Owen-Smith 
………………………………………………………………………………………………………………… 
ABSTRACT 
Background: The vulnerability of the pediatric inpatient population in United States healthcare settings 
establish a perfect environment for the acquisition and spread of methicillin-resistant Staphylococcus 
aureus (MRSA). Although infection prevention and control protocols have well been established for 
MRSA and for adult inpatients, there is a gap in literature in current guidelines on how to address MRSA 
prevention and control in pediatric inpatients.   
Objectives: To determine the effects of infection prevention and control strategies for preventing the 
transmission of methicillin-resistant Staphylococcus aureus (MRSA) in United States pediatric inpatient 
settings.   
Search methods: In June-August 2015, we searched Campbell Collaboration Library, Cochrane Library, 
PubMed, MEDLINE, Biological Abstracts, CINAHL Plus, and Web of Science for studies published 
between January of 2005 and December 2015 by using relevant key terms for pediatric patients (ex, 
children, infant, newborn, neonate) and prevention and control of MRSA.   
Selection criteria: All primary data studies on infection prevention and control interventions for healthcare 
associated MRSA in pediatric inpatient settings were eligible for inclusion.  
Data collection and analysis: Two review authors independently reviewed the results of the searches. 
Another review author was consulted for any discrepancies between categorization of articles. Data 
extraction was conducted by one review author and was checked by a second review author. 
Main results: 1,619 studies were initially identified, of which 21 studies met the criteria for inclusion.  Of 
the studies that met inclusion criteria, one was a randomized control trial, thirteen were retrospective cohort 
studies, four were before and after studies, two were prospective cohort studies and one was a retrospective 
case finding. Three studies (Song (2010), Robicsek (2009), and Gregory (2009)) found that Mupirocin or 
antibiotic treatment did not eradicate MRSA colonization consistently and were unsuccessful in eliminating 
continuing transmission of MRSA.  However, the study by Delaney found that there was a significant 
reduction in rates of S. aureus infection when comparing Mupirocin prophylactic period with the control 
period.  Another two studies (Constantini and Kjonegaard) found that screening was not identifying all of 
the MRSA cases, and that HA-MRSA infection rates did not decline after implementation of ICU 
screening, thus proving that this method was ineffective in regards to decreasing transmission and 
incidence of MRSA infections.  
Conclusion: There is a lack of research evaluating the effects on MRSA transmission of infection 
prevention and control strategies in pediatric inpatient settings. More resources should be devoted to 
understand the epidemiology of MRSA amongst the pediatric inpatient population as well as continued 
research interventions to establish prevention and control protocols for this vulnerable population.    
KEYWORDS Prevention, Control, MRSA, Neonates, Infant, Pediatrics, Children, Newborns, NICU, 
PICU
RSA is an opportunistic gram-
positive bacteria that has in 
recent years become a serious 
healthcare as well as community threat. 
In particular, MRSA is a common 
bacterial infection amongst children, 
especially in the NICU due to their 
susceptibility to infections.  Iwamoto et 
al., (2013) found that although there is 
an improvement due to the decrease in 
the severity of and risk of mortality as a 
result of infections, healthcare associated 
M 
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MRSA infections were not significantly 
reduced among pediatric populations 
from 2005-2010.  This indicates that 
there needs to be further research as to 
why there is an overall improvement 
among adults but not for pediatric 
inpatients.  It is important to study 
pediatric populations because according 
to Milstone et al., (2011) 8.5% of 
pediatric patients that were colonized 
with MRSA on admission developed a 
MRSA infection.  Even more staggering 
is the fact that 47% of patients who 
became colonized with MRSA in the 
pediatric ICU developed MRSA 
infections (Milstone et al., 2011).  In 
comparison, Hudson et al; (2012) found 
that the rates of MRSA carriage to be 6-
12% in general hospital patients and 9-
24% in ICUs.  Various strategies for 
prevention and eradication have been 
used with various rates of success.  
However, implementation of 
standardized prevention methods has yet 
to be developed specifically for 
pediatrics, even though there is a clear 
need for such protocols.  
 Guidelines for prevention of 
healthcare associated MRSA (HA-
MRSA) currently exist from the Center 
for Disease Control and Prevention, but 
there is limited evidence about best 
practices with respect to implementation 
for MRSA prevention among pediatric 
populations.  The purpose of this study 
was to conduct a systematic review in 
order to evaluate the current state of the 
science with respect to MRSA 
interventions in pediatric inpatient 
settings in the United States. 
Specifically, this study aimed to:  
1. Identify interventions for the 
prevention of hospital-
acquired MRSA in pediatrics 
in the United States 
2. Explore which prevention 
interventions appear to be 
most effective as defined by a 
decrease in transmission or 
incidence of MRSA 
infections 
3. Develop informed 
suggestions to researchers 
and policy makers in regards 
to current hospital-acquired 
MRSA prevention protocols 
for pediatrics 
METHODS 
This systematic review included 
literature found from 2005-2015 and 
specifically focused on inpatient 
pediatrics.    
Search Strategy 
With the help of the university 
librarian, the first author conducted 
scientific literature searches using the 
Campbell Collaboration Library, 
Cochrane Library, PubMed, MEDLINE, 
Biological Abstracts, CINAHL Plus, and 
Web of Science for studies published 
between January of 2005 and December 
2015 by using relevant key terms for 
pediatric patients (ex, children, infant, 
newborn, neonate) and prevention and 
control of MRSA.  All studies that were 
not in the English language were 
excluded for this systematic review.  
From this original search, we identified a 
total of 1,619 articles.  After compiling 
all sources and removing duplicate 
articles we had a total of 698 original 
articles.  
Study Selection 
Studies were required to meet the 
following criteria in order to be included 
in the review:  
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1. Conducted in the United States 
2. Evaluated the impact of an 
intervention for prevention 
and/or control of MRSA 
3. Included children age  0-17 years 
old 
4. Implemented in an inpatient 
setting    
Studies that did not collect primary 
data such as reviews, opinion articles, 
and letters to editors were excluded.  
The first round of review was 
based on screening titles and abstracts 
against the inclusion and exclusion 
criteria.  Two researchers who were 
blinded by each other’s categorization 
conducted this assessment.  Then after 
each researcher completed the first 
assessment, categorizations were 
compared and quality of categorization 
was measured by percent agreed upon 
(89%).   The articles that were not 
agreed upon were set aside and were 
included in the full text review.   
The second round of review was 
based on reading the full article in order 
to review any unclear abstracts.  During 
the second round of assessment, a third 
researcher was brought in to settle any 
discrepancies between those studies that 
were not agreed upon for categorization 
in the first round.  Also any articles that 
were met inclusion criteria were 
reviewed again in the second round to 
verify they fit criteria for inclusion.  
After the second round of assessment, 21 
articles met all criteria for inclusion.   
Validity assessment 
In order to assess the quality of 
all included studies, the first author 
completed the quality assessment form 
included in the article by Zara et al., 
(2000).  Parameters included in the 
assessment of study quality were based 
on six categories of common problems 
including descriptions, sampling, 
measurement, analysis, results, and 
other.  
Data abstraction and synthesis 
By using standardized extraction 
forms produced by Zara et al., (2000), 
the first author independently extracted 
all data.  The third and first author 
reviewed results of data abstraction form 
in order to summarize for systematic 
review. Discrepancies were discussed 
and resolved by consensus. 
 
RESULTS 
Description of Studies 
  
We followed the Preferred 
Reporting Items for Systematic Reviews 
(PRISM) guidelines (Moher, Liberati, 
Tetzlaff, Altman, & The PRISMA 
Group, 2010) in order to conduct this 
systematic review to best standards and 
to report results systematically.   
1,619 studies were originally 
identified, of which 21 studies met the 
criteria for inclusion.  Of the studies that 
met inclusion criteria, one was a 
randomized control trial, thirteen were 
retrospective cohort studies, four were 
single-group pre-posttest studies, two 
were prospective cohort studies and one 
was a retrospective case finding.  The 
study identification and data abstracting 
process is outlined in Figure 1.   
Eleven out of twenty one studies 
took place in the NICU, five were in a 
children’s hospital, three were at the 
entire hospital, and two were in hospital 
systems. Most studies reported MRSA 
colonization or infection as a percentage; 
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some studies reported patient-days at 
risk while others reported attack rates. 
 
Methodological quality of included 
studies 
 
Very few studies measured pre-
intervention MRSA incidence.  This is a 
major flaw in the studies analyzed in the 
fact that there is no comparison before 
intervention to see if the intervention 
plays a key role in MRSA transmission 
reduction.  Also, few studies actually 
measured hospital worker-related 
outcomes in order to see if healthcare 
practitioners adhered to interventions.  
Again, most studies did not assess pre-
intervention hand hygiene compliance 
rates, surveillance rates, or contact 
precaution adherence rates.  Another 
important aspect of the studies included 
that should be addressed is the fact that 
none of the studies separated each 
intervention piece.  Every study included 
multiple intervention types, so there is 
no way of separating interventions in 
order to see if individual intervention 
components would be effective on its 
own. 
Only one study was a 
randomized control trial, most were 
observational studies, and in most of the 
studies key details on the population 
demographics were not described.  
Through detailed team discussion we 
were able identify key results and the 
intervention types that we felt were most 
important, thus allowing us to classify 
studies based on intervention type and 
summarize the results.   
  
Hospital Worker-Related Outcome 
 
 Six studies identified healthcare 
workers as being colonized with MRSA 
and thus decolonized the healthcare 
worker effectively.  Three studies 
identified successful increase in hand 
hygiene compliance.  The study by Song 
et al; (2013) noted that sustaining hand 
hygiene at 80% or higher was associated 
with a 48% further reduction of MRSA 
in comparison with the study by 
Holzmann-Pazgal et al; (2011) that 
found significant improvement in hand 
hygiene compliance was not 
independently associated with reduction 
in MRSA transmission.  This shows that 
there is still some discrepancy in the 
results as to the effectiveness of worker-
related outcomes in relation to decrease 
in transmission and incidence of MRSA 
infections.   
 
 
 
Patient-Related Outcome 
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 Colonization rates varied 
amongst all studies with Murillo (2009) 
finding 9.3% of babies were colonized, 
Song (2010) found 7% that were 
colonized/infected, Khoury (2005) found 
21.4% colonized, and Kaushik (2014) 
found 57% were colonized at admission.   
 Three studies (Song (2010), 
Robicsek (2009), and Gregory (2009)) 
found that Mupirocin or antibiotic 
treatment did not eradicate MRSA 
colonization consistently and were 
unsuccessful in eliminating continuing 
transmission of MRSA.  However, the 
study by Delaney found that there was a 
significant reduction in rates of S. aureus 
infection when comparing Mupirocin 
prophylactic period with the control 
period.   
 Another two studies (Constantini 
and Kjonegaard) found that screening 
was not identifying all of the MRSA 
cases, and that HA-MRSA infection 
rates did not decline after 
implementation of ICU screening, thus 
proving that this method was ineffective 
in regards to decreasing transmission 
and incidence of MRSA infections. 
 
DISCUSSION 
 
Strengths of review 
 This study has several strengths 
including an extensive, thorough search 
of current literature of which two 
blinded reviewers categorized articles in 
order to reduce misclassification bias.  
Another strength found in this review is 
that each article that met inclusion 
criteria also went through a quality 
assessment in order to rank articles by 
best methods.  Another strength of this 
review is that the focus on the study 
population is very precise, thus allowing 
the results to be directly applied to 
children in inpatient settings.   
 
Limitations of review 
 
 Publication bias is always an 
important bias to address in systematic 
reviews.  Publication bias is when 
studies that have statistically significant 
results are more likely to be published in 
comparison to those whose results are 
not statistically significant.  Thus for the 
purpose of this review, we must address 
the fact that we were only able to collect 
articles that were published in journals, 
thus excluding all research that did not 
make it to journal acceptance.   
 Another bias that that needs to be 
addressed is the chance of 
misclassification bias due to researcher 
misclassifying articles by inclusion 
criteria.   
 This study also has limitations in 
the fact that it cannot be generalized to 
outpatients or adult MRSA patients.   
 
Implications for health policy, clinical 
care, and future research 
 
This systematic review has 
shown that there is much research that is 
still needed in order to find a solution to 
reduce transmission of MRSA in 
pediatric inpatient settings.  The 
implications that this systematic review 
has are limited since the majority of the 
studies included were observational and 
tested multiple intervention components 
simultaneously.   
Given the heavy reliance on 
Mupirocin as the topical antibiotic of 
choice when treating MRSA, more 
research needs to be conducted on the 
efficacy of treatment among this 
subpopulation.  More research also 
needs to be conducted to investigate 
whether decolonization is effective and 
cost-effective in preventing transmission 
of MRSA amongst pediatric inpatients.   
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The article by Kho on 
implementing an email alert system in 
hospital systems seems to be a very 
effective approach that allows for 
cohorting infected or colonized patients 
immediately when they are admitted, 
thus reducing transmission.  More 
research should be conducted to see if 
this system is effective in high MRSA 
incidence areas.    
One suggestion for future 
research would be to separate NICU 
patients and pediatrics, as NICUs have 
different practices (such as bed sharing 
with twins) and are at higher risk due to 
their compromised immune systems in 
comparison to those pediatric inpatients.   
 
CONCLUSION 
 
This systematic review provides 
some evidence that Mupirocin 
decolonization is not effective in 
reducing transmission of MRSA 
amongst pediatric inpatients.  Another 
key report is that universal surveillance 
may not be as effective as originally 
thought, and thus mixed method 
prevention interventions should be 
instituted in order to have the best 
patient outcome.   However, much 
research is needed on the pediatric 
population in order to develop guidelines 
in order to prevent transmission of 
MRSA amongst pediatric inpatients. 
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